A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib

被引：65

作者：

Cha, Yoon Jin ^{[1
]}

Cho, Byoung Chul ^{[2
]}

Kim, Hye Ryun ^{[2
]}

Lee, Hye-Jeong ^{[3
]}

Shim, Hyo Sup ^{[1
]}

机构：

[1] Yonsei Univ, Severance Hosp, Dept Pathol, Coll Med, Seoul, South Korea

[2] Yonsei Univ, Yonsei Canc Ctr, Dept Oncol, Coll Med, Seoul, South Korea

[3] Yonsei Univ, Severance Hosp, Dept Radiol, Coll Med, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 05期

关键词：

Lung adenocarcinoma; Anaplastic lymphoma kinase; Crizotinib; Resistance; Small cell lung carcinoma;

D O I：

10.1016/j.jtho.2015.12.097

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Histologic changes can be involved in resistance to anticancer drugs. Transformation to small cell lung carcinoma (SCLC) following treatment with EGFR tyrosine kinase inhibitors has been reported in patients with EGFR-mutant lung adenocarcinoma. Herein, we report a case of ALK-rearranged lung adenocarcinoma with SCLC-like histology in a metastatic abdominal nodule that was resistant to crizotinib therapy. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：E55 / E58

页数：7

共 50 条

[21] ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report
Qiu, Ye
Li, Bixun
Zhang, Yihong
Guo, Xiaoyun
Xiang, Chunzhi
Wang, Congshui
Lu, Yang
Ren, Shuang
Zhao, Juan
MEDICINE, 2019, 98 (11)
[22] Xanthogranutomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer
Brosseau, S.
Gounant, V.
Choudat, L.
Pluvy, J.
Zalcman, G.
Khalil, A.
DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2018, 99 (04) : 267 - 268
[23] Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
Zhang, Yan
Wang, Yan
Li, Junling
Hao, Xuezhi
Ma, Di
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S377 - S377
[24] Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors
Levacq, Delphine
D'Haene, Nicky
de Wind, Roland
Remmelink, Myriam
Berghmans, Thierry
LUNG CANCER, 2016, 102 : 38 - 41
[25] CONVERSION OF ADENOCARCINOMA TO SMALL CELL CARCINOMA-LIKE BY REPROGRAMMING
Borges, Gisely
Vencio, Eneida
Quek, Sue-Ing
Chen, Adeline
Salvanha, Diego
Vencio, Ricardo
Nguyen, Holly
Vessella, Robert
Cavanaugh, Christopher
Ware, Carol
Troisch, Pamela
Liu, Alvin
JOURNAL OF UROLOGY, 2016, 195 (04): : E819 - E819
[26] Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib
Muller, Ittai B.
De Langen, Adrianus J.
Honeywell, Richard J.
Giovannetti, Elisa
Peters, Godefridus J.
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 147 - 157
[27] Crizotinib rechallenge reverses MET amplification-mediated resistance to ALK inhibitors in a patient with advanced ALK-rearranged non-small cell lung cancer: a case report
Wang, Rixiang
Chen, Weizhuang
Jiao, Wenrui
Ren, Feng
Wu, Hongcheng
Wu, Shibo
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (08): : 6163 - 6167
[28] Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
Kim, Soyeon
Kim, Tae Min
Kim, Dong-Wan
Go, Heounjeong
Keam, Bhumsuk
Lee, Se-Hoon
Ku, Ja-Lok
Chung, Doo Hyun
Heo, Dae Seog
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (04) : 415 - 422
[29] Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma
Caumont, Charline
Veillon, Remi
Gros, Audrey
Laharanne, Elodie
Begueret, Hugues
Merlio, Jean-Philippe
LUNG CANCER, 2016, 92 : 15 - 18
[30] Non-invasive detection of crizotinib resistance in ALK-rearranged lung adenocarcinoma directs treatment with next-generation ALK inhibitors.
Ihuegbu, Nnamdi
Banks, Kimberly C.
Fairclough, Stephen R.
Zill, Oliver A.
Chudova, Darya
Lanman, Richard Burnham
Blakely, Collin M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →